Samantha Smith
Family · Wichita, KSNPI 1972003184
Payments from drug & device makers
Across 60 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$273
- Lilly USA, LLC$120
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$101
- GSK$76
- Vanda Pharmaceuticals Inc.$46
- Bayer$45
- plus $379 from 16 others
What the payments were for
- Food & beverage$1,040100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $273 |
| Lilly USA, LLC | 8 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| GSK | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Bayer | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| AbbVie | 3 | $42 |
| Astellas Pharma US Inc | 2 | $42 |
| Merck | 2 | $28 |
| Seqirus USA Inc | 1 | $27 |
| Ardelyx, Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $23 |
| Exact Sciences | 1 | $19 |
| Medtronic | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Amgen | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Novartis | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$1,040 in reported general payments places this provider in the 70th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $7,378 |
| Paliperidone ErPaliperidone | 12 | $1,561 |
| Gabapentin | 19 | $234 |
| Cyproheptadine Hcl | 23 | $232 |
| Atorvastatin Calcium | 47 | $179 |
| Fluvoxamine Maleate | 11 | $142 |
| Levothyroxine Sodium | 34 | $138 |
| Cyclobenzaprine Hcl | 12 | $93 |
| Famotidine | 13 | $91 |
| Omeprazole | 18 | $85 |
| Alprazolam | 12 | $81 |
| Lisinopril | 15 | $78 |
| Furosemide | 12 | $41 |
| Metformin Hcl | 21 | $35 |
| Amlodipine Besylate | 22 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $16 | $7,37812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,579 family providers in Kansas.
Other family in Wichita
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Mary GarciaWichita$24K
- Jennifer NeelWichita$15K
- Amanda AstWichita$9K
- Jennifer MartinWichita$8K
- Lauren CoteWichita$7K
- Mimi TranWichita$6K
- Kara NabboutWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.